TEL AVIV — February 20, 2026 — Leads & Copy — Nasus Pharma Ltd. (NYSE: NSRX) will participate in investor conferences in February and March.
Management from the clinical-stage pharmaceutical company will attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 1:20 p.m. ET. The conference will be virtual, and interested parties can register at https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/KoYPJS8x3zqMuXPHfEHoSY. Dan Teleman, Chief Executive Officer, will be the speaker for the company presentation.
Nasus Pharma will also participate in the BIO Investment & Growth Summit on March 2, 2026, at 10:15 a.m. ET in Miami, FL. Teleman will also be the speaker here. The final conference will be the Citizens Life Sciences Conference on March 11, 2026, at 3:25 p.m. ET in Miami, FL, with Teleman as the speaker.
Nasus Pharma is developing intranasal powder products that address acute medical conditions. NS002, the company’s intranasal powder Epinephrine product candidate, is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. The company’s proprietary powder-based intranasal (“PBI”) technology is designed for drug delivery, leveraging the nasal cavity’s vascular network for absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.
Nasus management will be available for one-on-one meetings during the conferences. Interested parties should contact their conference representative to arrange a meeting.
Source: Nasus Pharma
